ArticleClinical pharmacokinetics2022

Assessment of the Pharmacokinetics and Safety of Spesolimab, a Humanised Anti-interleukin-36 Receptor Monoclonal Antibody, in Healthy Non-Japanese and Japanese Subjects: Results from Phase I Clinical Studies.

David Joseph et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.